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We and others have previously shown that microarrays can be used to identify
gene expression proﬁles that discriminate between oestrogen receptor (ER)-
positive and -negative breast tumours. However, these studies focused only on
ER status as a binary variable and did not address the relationship of gene
expression data to the continuous range of ER protein values. Here, we present a
novel approach using expression data and artiﬁcial neural networks to
accurately predict the ER protein values on a continuous scale in 48 primary
breast cancers. Furthermore, this method may be used to determine a more
biologically and therapeutically relevant threshold for the ER protein level to
redeﬁne ER-positive and ER-negative classes. In the same way, we studied the
prediction of other prognostic parameters, such as the progesterone receptor and
S phase fraction. Interestingly, there was a consistent reciprocal relationship in
the expression levels of the genes that are important for prediction of both ER
protein and the fraction of cells in S phase. However, it is clear that the ER
status has the strongest impact on the gene expression proﬁle of a tumour
suggesting that these two groups are biologically very distinct and should
perhaps be treated separately in breast cancer management.
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Many novel endocrine therapies are licensed for use in advanced breast cancer.
Their eﬃcacy in this setting has led to trials of adjuvant therapy, many of
which have shown a reduction in contralateral breast cancers, hence, the real
hope that hormonal therapy has an important role to play in chemopreven-
tion. Bilateral prophylactic mastectomy and/or regular surveillance are the
only other options available to women who are at high genetic risk of breast
cancer but these are not acceptable to all and can impact on certain aspects of
quality of life (QoL). Several clinical trials have compared the eﬃcacy of
selective oestrogen receptor modulators (SERMs) and aromatase inhibitors in
preventing breast cancer in high-risk women. The putative beneﬁts of this
approach have to be weighed against potentially serious side-eﬀects,
especially on bones and the endometrium. The rigorous assessment of QoL
issues such as: – menopausal symptoms, the impact that treatment has on
sexual activity, mood state and cognitive function, is also vital in this
essentially ‘well’ population of women. In this talk, some of the QoL
results from the tamoxifen chemoprevention trials will be reviewed and the
current IBIS-II (International Breast Cancer Intervention Study) trial of
anastrozole vs. placebo will also be discussed. In the IBIS-II trial, 700
post-menopausal women will complete measures of memory, mood and
cognition at baseline, 6 months, 2 and 5 years. The assessment comprises
four tests of verbal memory and attention, intelligence quotient (IQ)
measurements, self-report evaluations on mood state, cognitive failures
and endocrine symptoms.
The aim of interventions in breast cancer has always been to improve the quality of
women’s lives, either by curing themof their disease or ameliorating its worst eﬀects.
Now that we have a realistic prospect of preventing the disease, wemust ensure that
this does not result in the introduction of other deleterious eﬀects on QoL.
doi:10.1016/j.ejcsup.2004.08.022
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